Clinical Trial: BLAZE-Limiting Approach in NMOSD
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Neuromyelitis Optica Spectrum Disorders (NMOSD)
Study Type: OBSERVATIONAL
Official Title: Eculizumab for Blaze-limiting Approach in NMOSD: A Prospective Study
Brief Summary:
This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651).Between October 2023 (when eculizumab was approved for NMOSD in China) and February 2025, 26 consecutive patients with AQP4-IgG-positive NMOSD received eculizumab, and 9 of them were included in this study.
Read more